John Proudfoot - Concepedia

Author

John Proudfoot

Boehringer Ingelheim (United States)ORCID

Also Known As

J Proudfoot, J. PROUDFOOT, J. Proudfoot, J. R. PROUDFOOT, J.R. Proudfoot, John Proudfoot, John R Proudfoot, John R. Proudfoot, John Robert Proudfoot, Proudfoot, John

431

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

Boehringer Ingelheim (United States)Boehringer Ingelheim (Germany)Boehringer Ingelheim (Japan)Boehringer Ingelheim (France)Stanford University

About

John Proudfoot is an author at Boehringer Ingelheim (United States) specializing in drug discovery, pharmacology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	1.3K
2	Biochemistry	15	21	726
3	Natural Sciences	14	20	812
4	Engineering	12	14	327
5	Biology	3	3	48

John Proudfoot

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Drugs, leads, and drug-likeness: an analysis of some recently launched drugs John Proudfoot Bioorganic & Medicinal Chemistry Letters Substance AbuseDrug IntelligenceAddictionMedicineDrug Policy	2002	251
Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones Karl D. Hargrave, John Proudfoot, Karl Grozinger, Journal of Medicinal Chemistry Molecular BiologySmall SubstituentsHeterocycle ChemistryAntiviral DrugPharmaceutical Chemistry	1991	208
A novel, dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site Joseph C. Wu, Thomas C. Warren, Julian Adams, Biochemistry	1991	181
Glossary of terms used in medicinal chemistry. Part II (IUPAC Recommendations 2013) Derek R. Buckle, Paul Erhardt, C. Robin Ganellin, Pure and Applied Chemistry Systems PharmacologyMedicinal ChemistryDrug RepositioningIupac Recommendations 2013Pharmaceutical Science	2013	151
The evolution of synthetic oral drug properties John Proudfoot Bioorganic & Medicinal Chemistry Letters Pharmaceutical ScienceDrug DesignMedicineRational Drug DesignSynthetic Biology	2005	124
A structure–Permeability study of small drug-like molecules Thomas Fichert, Mehran Yazdanian, John Proudfoot Bioorganic & Medicinal Chemistry Letters Small MoleculesSmall Molecule LibraryStructure–permeability StudyMolecular ModelingBiophysics	2003	91
Glossary of terms used in biomolecular screening (IUPAC Recommendations 2011) John Proudfoot, Olivier Nosjean, Jan Blanchard, Pure and Applied Chemistry Pharmaceutical ResearchEngineeringBiomolecular ToolPathologyScreening Process	2011	86
Mechanisms of Transport and Structure-Permeability Relationship of Sulfasalazine and Its Analogs in Caco-2 Cell Monolayers Earvin Liang, John Proudfoot, Mehran Yazdanian Pharmaceutical Research	2000	81
Ligands for the Tyrosine Kinase p56<i><sup>lck</sup></i> SH2 Domain: Discovery of Potent Dipeptide Derivatives with Monocharged, Nonhydrolyzable Phosphate Replacements Pierre L. Beaulieu, Dale R. Cameron, Jean‐Marie Ferland, Journal of Medicinal Chemistry Molecular BiologySignal Transduction EventsPotent DipeptideReceptor Tyrosine KinaseSrc Family	1999	57
Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors Alexander Heim‐Riether, Steven J. Taylor, Shuang Liang, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryMedicineNon-zn-chelating Mmp-13 InhibitorsNew ClassPharmacotherapy	2009	50

Page 1